article Open AccessTop 1% cited
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · Vol. 13(3) · pp. 239–246
Rafael Rosell✉(Institut Català d'Oncologia)Enric Carcereny(Institut Català d'Oncologia)Radj Gervais(Centre François Baclesse)A. Vergnenègre(Hôpital Dupuytren)Bartomeu Massutí(Hospital General Universitario de Alicante Doctor Balmis)Enriqueta Felip(Vall d'Hebron Hospital Universitari)Ramón Palmero(Institut Català d'Oncologia)Ramón García-Gómez(Hospital General Universitario Gregorio Marañón)Cinta Pallarés(Hospital de Sant Pau)José Miguel Sánchez(Research Institute Hospital 12 de Octubre)Rut Porta(Institut Català d'Oncologia)Manuel Cobo(Hospital Doctor José Molina Orosa)Pilar Garrido(Hospital Universitario Ramón y Cajal)Flavia Longo(Policlinico Umberto I)Teresa Morán(Institut Català d'Ornitologia)Amelia Insa(Hospital Clínico Universitario de Valencia)Filippo de Marinis(Azienda Ospedaliera San Camillo-Forlanini)R. Corre(Hôpital Pontchaillou)Isabel Bover(Hospital Son Llatzer)Alfonso IllianoÉric Dansin(Centre Oscar Lambret)Javier de Castro(Hospital Universitario La Paz)Michèle MilellaNoemı́ Reguart(Hospital Clínic de Barcelona)Giuseppe Altavilla(Azienda Ospedaliera Universitaria Policlinico "G. Martino")Ulpiano Jiménez(Hospital Universitario de La Princesa)Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda)Miguel Ángel Moreno(Complejo Hospitalario de Jaén)Josefa Terrasa(Hospital Universitario Son Dureta)José Muñoz-Langa(Hospital Universitario Doctor Peset)Javier Valdivia(Hospital Universitario Virgen de las Nieves)Dolores Isla(Hospital Clínico Universitario Lozano Blesa)Manuel Dómine(Hospital Universitario Fundación Jiménez Díaz)Olivier Molinier(Centre Hospitalier du Mans)Julien Mazières(Hôpital Larrey)Nathalie Baize(Centre Hospitalier Universitaire d'Angers)Rosario García‐CampeloG. Robinet(Centre Hospitalier Régional Universitaire de Brest)Delvys Rodríguez‐Abreu(Hospital Universitario Insular de Gran Canaria)Guillermo López-Vivanco(Hospital de Cruces)Vittorio Gebbia(La Maddalena)Lioba Ferrera-DelgadoP. Bombaron(Centre Hospitalier de Mulhouse)Reyes Bernabé(Hospital Universitario de Valme)Alessandra Bearz(Centro di Riferimento Oncologico)Á. Artal(Hospital Universitario Miguel Servet)Enrico Cortesi(Sapienza University of Rome)Christian Rolfo(Clinica Rotger)María Sanchez-Ronco(Universidad de Alcalá)Ana Drozdowskyj(Pivotal (Spain))Cristina Queralt(Institut Català d'Ornitologia)Itziar de Aguirre(Institut Català d'Oncologia)José Luis Ramírez(Institut Català d'Oncologia)José Javier Sánchez(Universidad Autónoma de Madrid)Miguel Ángel Molina‐Vila(USP Institut Universitari Dexeus)Miquel Tarón(USP Institut Universitari Dexeus)Luis Paz‐Ares(Hospital Universitario Virgen del Rocío)
Lung Cancer Treatments and MutationsLung Cancer Research StudiesColorectal Cancer Treatments and StudiesErlotinibMedicineDocetaxelInternal medicineOncologyCarboplatinGemcitabineLung cancerChemotherapyPopulation
MeSH terms
Erlotinib HydrochlorideDocetaxelGemcitabineAdministration, OralAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDrug Administration ScheduleEuropeExonsFemaleHumansLung Neoplasms
Citations
5,500
FWCI
372.84
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · 768 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · 1,573 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,350 citations
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
The Lancet Oncology · 2014 · 1,963 citations
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2012 · 928 citations
References
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology · 2009 · 4,101 citations
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences · 2004 · 4,332 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology · 2011 · 4,075 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
Related articles
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology · 2007 · 3,845 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
